BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 31295281)

  • 1. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF
    Lin Y; Luo YK; Li J; Ren XY; Wang HW
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology-Ultrasonography Risk-Stratification Scoring System Based on Fine-Needle Aspiration Cytology and the Korean-Thyroid Imaging Reporting and Data System.
    Hong MJ; Na DG; Baek JH; Sung JY; Kim JH
    Thyroid; 2017 Jul; 27(7):953-959. PubMed ID: 28463597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of Ultrasound Patterns by K-TIRADS and 2015 ATA Guidelines in Risk Stratification of Thyroid Nodules and Follicular Lesions of Undetermined Significance.
    Hong HS; Lee JY
    AJR Am J Roentgenol; 2019 Aug; 213(2):444-450. PubMed ID: 31039023
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does a higher American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) score forecast an increased risk of malignancy? A correlation study of ACR TI-RADS with FNA cytology in the evaluation of thyroid nodules.
    Modi L; Sun W; Shafizadeh N; Negron R; Yee-Chang M; Zhou F; Simsir A; Sheth S; Brandler TC
    Cancer Cytopathol; 2020 Jul; 128(7):470-481. PubMed ID: 32078249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
    Rosario PW
    Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Stratification in Patients With Follicular Neoplasm on Cytology: Use of Quantitative Characteristics and Sonographic Patterns.
    Wu MH; Chen KY; Hsieh MS; Chen A; Chen CN
    Front Endocrinol (Lausanne); 2021; 12():614630. PubMed ID: 33995270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
    Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the modification of the diagnostic criteria in the 2017 Bethesda System for Reporting Thyroid Cytopathology: a report of a single institution in Japan.
    Higuchi M; Hirokawa M; Kanematsu R; Tanaka A; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Endocr J; 2018 Dec; 65(12):1193-1198. PubMed ID: 30282887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients.
    Arva NC; Deitch SG
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach to Bethesda system category III thyroid nodules according to US-risk stratification.
    Kim J; Shin JH; Oh YL; Hahn SY; Park KW
    Endocr J; 2022 Jan; 69(1):67-74. PubMed ID: 34408101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma?
    Castellana M; Piccardo A; Virili C; Scappaticcio L; Grani G; Durante C; Giovanella L; Trimboli P
    Cancer Cytopathol; 2020 Apr; 128(4):250-259. PubMed ID: 31899594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS): a study applying Thyroid Imaging Reporting and Data System (TIRADS).
    Yoon JH; Kwon HJ; Kim EK; Moon HJ; Kwak JY
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):275-82. PubMed ID: 26639612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.
    Marina M; Zatelli MC; Goldoni M; Del Rio P; Corcione L; Martorana D; Percesepe A; Bonatti F; Mozzoni P; Crociara A; Ceresini G
    J Endocrinol Invest; 2021 Dec; 44(12):2635-2643. PubMed ID: 33860907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.